1700012G19Rik Inhibitors
Chemical inhibitors of 1700012G19Rik can exert their effects through various mechanisms, each targeting a distinct aspect of cellular signaling pathways. Palbociclib, by selectively inhibiting cyclin-dependent kinases CDK4 and CDK6, can impair the cell cycle progression at the G1 phase, which would in turn affect the function of 1700012G19Rik if its activity is tied to these checkpoints. Trametinib and PD98059, as inhibitors of MEK1/2, along with U0126, can reduce ERK pathway signaling, which could be crucial for 1700012G19Rik's function if it is linked to this pathway. By preventing the activation of MEK, these inhibitors would curtail the downstream signaling cascade necessary for 1700012G19Rik's function. SB203580 and SP600125 intervene in the MAPK signaling pathways, with SB203580 selectively inhibiting p38 MAP kinase, and SP600125 targeting the c-Jun N-terminal kinase (JNK). The inhibition of these kinases can alter the stress response and other signaling processes, potentially affecting 1700012G19Rik if it is a part of these pathways.
LY294002, as a potent inhibitor of phosphoinositide 3-kinases, disrupts the PI3K/AKT pathway, which may be essential for the signaling or stability of 1700012G19Rik. Rapamycin, by suppressing mTOR, could also influence 1700012G19Rik's function if it is involved in cell growth or survival signals that require mTOR activity. Dasatinib and PP2, which target Src family kinases, can interfere with signaling cascades that are mediated by these kinases. If 1700012G19Rik's activity is dependent on Src family kinase signaling, the inhibition by these chemicals would lead to a functional inhibition of the protein. Additionally, Y-27632 targets the Rho-associated protein kinase (ROCK), and if 1700012G19Rik is regulated by the Rho/ROCK pathway, this inhibitor would impair the necessary signaling for 1700012G19Rik's function in cellular processes such as motility or apoptosis. Each inhibitor, by acting on its specific target, can contribute to the functional inhibition of 1700012G19Rik through a distinct but interconnected web of cellular pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. 1700012G19Rik, involved in cell cycle progression, would be functionally inhibited as Palbociclib inhibits CDKs that are necessary for cell cycle G1 phase progression, thereby preventing the protein's associated cell cycle functions. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a reversible inhibitor of MEK1/2 activation and kinase activity, part of the MAPK/ERK pathway. By inhibiting MEK, it can reduce ERK pathway signaling which could be crucial for 1700012G19Rik function if the protein's activity is linked to this pathway, resulting in a functional inhibition of 1700012G19Rik by limiting its downstream signaling reliance on MEK/ERK. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 disrupts the PI3K/AKT pathway which may be essential for 1700012G19Rik signaling or stability, thereby functionally inhibiting 1700012G19Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, which can suppress the mTOR pathway that is potentially involved in the regulation or activity of 1700012G19Rik. Inhibition of mTOR can result in the functional inhibition of 1700012G19Rik by preventing its activity related to cell growth, proliferation, or survival signals that require mTOR function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which in turn reduces the activity of ERK1/2. If 1700012G19Rik is functionally dependent on the MEK/ERK signaling pathway for its activity, inhibition by PD98059 would result in functional inhibition of 1700012G19Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. Inhibition of p38 MAP kinase can lead to functional inhibition of 1700012G19Rik if the protein is involved in or regulated by the p38 MAPK stress response pathway, as it would inhibit the pathway's ability to phosphorylate substrates involved in stress responses, potentially including 1700012G19Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is part of the MAPK signaling pathways, which if involved in the regulation or activity of 1700012G19Rik, would lead to functional inhibition of 1700012G19Rik by inhibiting JNK-mediated signaling processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src family kinases are involved in various cell signaling pathways. If 1700012G19Rik is part of a signaling cascade mediated by Src family kinases, Dasatinib would functionally inhibit 1700012G19Rik by preventing Src kinase signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. If 1700012G19Rik activity is dependent on Src family kinase signaling, inhibition by PP2 would lead to functional inhibition of 1700012G19Rik by blocking the necessary tyrosine kinase activity for its signaling or regulatory functions. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, and by inhibiting MEK, it indirectly inhibits ERK1/2 activity. If the MEK/ERK pathway is necessary for 1700012G19Rik's function, U0126 would lead to functional inhibition of 1700012G19Rik by impairing the necessary MEK/ERK signaling. | ||||||